• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Killeen Matthew

    9/8/21 7:03:55 PM ET
    $CHAQ
    Business Services
    Finance
    Get the next $CHAQ alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Killeen Matthew

    (Last) (First) (Middle)
    C/O RENOVACOR, INC.
    P.O. BOX 8142

    (Street)
    GREENWICH CT 06836

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Renovacor, Inc. [ RCOR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Scientific Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    09/03/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option $7.73 09/03/2021 A 194,049 (1) 09/03/2031 Common Stock 194,049 $0 194,049 D
    Explanation of Responses:
    1. The stock option will vest and become exercisable in full on September 3, 2025, with 25% vesting on March 3, 2022, and the remainder vesting in equal monthly installments on the 3rd of each month for the remaining 42 months, subject to the continuous service of the Reporting Person on such vesting date.
    /s/ Joseph Carroll, as attorney-in-fact 09/08/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CHAQ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHAQ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHAQ
    SEC Filings

    View All

    SEC Form S-1 filed by Chardan Healthcare Acquisition 2 Corp.

    S-1 - Renovacor, Inc. (0001799850) (Filer)

    10/15/21 5:10:14 PM ET
    $CHAQ
    Business Services
    Finance

    Chardan Healthcare Acquisition 2 Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Renovacor, Inc. (0001799850) (Filer)

    9/30/21 9:34:23 AM ET
    $CHAQ
    Business Services
    Finance

    Chardan Healthcare Acquisition 2 Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Unregistered Sales of Equity Securities, Changes in Registrant’s Certifying Accountant, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhibits

    8-K - Renovacor, Inc. (0001799850) (Filer)

    9/9/21 5:16:25 PM ET
    $CHAQ
    Business Services
    Finance

    $CHAQ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange

    Common stock and warrants of the combined company, renamed Renovacor, Inc., will commence trading on September 3, 2021 on the NYSE under ticker symbols "RCOR" and "RCOR.WS", respectively. Gross proceeds from the transaction totaled approximately $95.1 million. Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the closing of its previously announced business combination with Chardan Healthcare Acquisition 2 Corp. (NYSE:CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Cap

    9/2/21 3:08:00 PM ET
    $CHAQ
    Business Services
    Finance

    Chardan Healthcare Acquisition 2 Corp. Announces Stockholder Approval Of Business Combination With Renovacor, Inc.

    NEW YORK, Sept. 1, 2021 /PRNewswire/ -- Chardan Healthcare Acquisition 2 Corp. (NYSE:CHAQ) ("CHAQ"), a special purpose acquisition company sponsored by Chardan Capital Markets ("Chardan"), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the "Special Meeting"), regarding the proposed business combination with Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants. CHAQ reported that all of the various proposals giving effect to

    9/1/21 4:42:00 PM ET
    $CHAQ
    Business Services
    Finance

    Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

    NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc. The closing of the merger is expected to occur in the third quarter of 2021. "Matt's extensive experience discovering, researching and developing

    8/25/21 3:14:00 PM ET
    $CHAQ
    Business Services
    Finance

    $CHAQ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Needham Thomas E. Jr.

    4 - Renovacor, Inc. (0001799850) (Issuer)

    9/8/21 8:51:00 PM ET
    $CHAQ
    Business Services
    Finance

    SEC Form 3 filed by new insider Needham Thomas E. Jr.

    3 - Renovacor, Inc. (0001799850) (Issuer)

    9/8/21 8:50:10 PM ET
    $CHAQ
    Business Services
    Finance

    SEC Form 4 filed by Lau Joan

    4 - Renovacor, Inc. (0001799850) (Issuer)

    9/8/21 7:04:45 PM ET
    $CHAQ
    Business Services
    Finance

    $CHAQ
    Leadership Updates

    Live Leadership Updates

    View All

    Chardan Healthcare Acquisition 2 Corp. Announces Renovacor's Appointment of Matt Killeen, Ph.D., as Chief Scientific Officer

    NEW YORK, Aug. 25, 2021 /PRNewswire/ -- Renovacor, Inc. ("Renovacor"), an early–stage biotechnology company developing adeno-associated virus (AAV)–based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Matt Killeen, Ph.D., as chief scientific officer (CSO), effective as of September 1, 2021. Chardan Healthcare Acquisition 2 Corp. (CHAQ) previously announced on March 23, 2021 that it entered into a definitive merger agreement with Renovacor, Inc. The closing of the merger is expected to occur in the third quarter of 2021. "Matt's extensive experience discovering, researching and developing

    8/25/21 3:14:00 PM ET
    $CHAQ
    Business Services
    Finance

    Renovacor Announces the Appointment of Elizabeth White, Ph.D., as Chief Business Officer and Senior Vice President of Operations

    PHILADELPHIA, July 19, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Elizabeth (Beth) White, Ph.D., as chief business officer and senior vice president of operations. "Beth is a proven industry professional who possesses a unique blend of business, scientific and drug strategy experience from leadership roles in global pharma and biotech companies that will guide the development of our lead candidate, REN-001," said Magdalene Cook, M.D., chief exec

    7/19/21 7:00:00 AM ET
    $CHAQ
    Business Services
    Finance

    Renovacor Announces the Appointment of Jiwen Zhang, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance

    PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) -- Renovacor, Inc. ("Renovacor"), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jiwen Zhang, Ph.D., as senior vice president, regulatory affairs and quality assurance. "Jiwen's extensive regulatory expertise and experience advancing AAV-based gene therapies into the clinic will be invaluable assets for Renovacor," said Magdalene Cook, M.D., chief executive officer of Renovacor. "She has successfully built regulatory affairs functions at companies of varying s

    7/12/21 7:00:00 AM ET
    $CHAQ
    Business Services
    Finance

    $CHAQ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Chardan Healthcare Acquisition 2 Corp.

    SC 13D - Renovacor, Inc. (0001799850) (Subject)

    9/13/21 2:16:41 PM ET
    $CHAQ
    Business Services
    Finance

    SEC Form SC 13G/A filed by Chardan Healthcare Acquisition 2 Corp. (Amendment)

    SC 13G/A - Renovacor, Inc. (0001799850) (Subject)

    9/7/21 5:01:10 PM ET
    $CHAQ
    Business Services
    Finance

    SEC Form SC 13G filed by Chardan Healthcare Acquisition 2 Corp.

    SC 13G - Chardan Healthcare Acquisition 2 Corp. (0001799850) (Subject)

    7/29/21 3:21:28 PM ET
    $CHAQ
    Business Services
    Finance